A 49-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer and Liver and Lung Metastases

Anne P. O'Dea, MD, presents the case of a 49-year-old woman with HR+/HER2- metastatic breast cancer and offers initial impressions on the patient’s risk and prognosis.

A hematologist-oncologist discusses the importance of biomarker testing in breast cancer, provides clinical insights on how to prioritize different testing assays, and outlines the roles of circulating tumor DNA and repeat testing.

Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.

Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.

Anne O’Dea, MD, discusses factors that contribute to second-line treatment selection and offers clinical insights on improving outcomes for patients being treated for breast cancer.